*Retrospective study of 70 consecutive patients
with haematologic malignancies who had
definite or probable mucormycosis from
January 1989 to April 2006 and who had
received initial treatment with amphotericin B.
Results were analysed to determine the impact
of delaying effective amphotericin B-based
therapy, compared with other clinical predictors
of outcome among patients with mucormycosis.
Given the challenges of clinically distinguishing
mucormycosis from aspergillosis, timely
initiation of amphotericin B was recommended.
Delayed treatment was defined as ≥6 days
after diagnosis; early treatment was defined
as <6 days after diagnosis.12
with haematologic malignancies who had
definite or probable mucormycosis from
January 1989 to April 2006 and who had
received initial treatment with amphotericin B.
Results were analysed to determine the impact
of delaying effective amphotericin B-based
therapy, compared with other clinical predictors
of outcome among patients with mucormycosis.
Given the challenges of clinically distinguishing
mucormycosis from aspergillosis, timely
initiation of amphotericin B was recommended.
Delayed treatment was defined as ≥6 days
after diagnosis; early treatment was defined
as <6 days after diagnosis.12
**Please refer to the Liposomal Amphotericin B Summary of Product
Characteristics for detailed information on safety profile.
Characteristics for detailed information on safety profile.
Footnote
